AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

GILD · NASDAQ · Drug Manufacturers - General

Gilead Sciences (GILD)

Develops HIV antivirals, liver-disease medicines, and oncology therapies including CAR-T treatments.

$152.11

After-hours close−0.56 (−0.37%)

At close$152.67(+1.40%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	7,050	7,114	6,686	6,953	7,545	7,569	6,667	7,081	7,769	7,924	6,960	7,803
Cost of revenue	1,565	2,090	1,552	1,544	1,574	1,581	1,540	1,501	1,569	1,624	1,445	1,579
Gross profit	5,485	5,024	5,134	5,409	5,971	5,988	5,127	5,580	6,200	6,300	5,515	6,224
	2,862	3,412	9,456	2,765	5,083	3,536	2,890	3,106	2,873	3,312	2,929	16,618
Research & development	1,457	1,408	1,520	1,351	1,395	1,641	1,379	1,491	1,346	1,584	1,372	1,764
	1,315	1,580	1,375	1,377	1,410	1,861	1,258	1,365	1,357	1,728	1,451	1,921
Selling & marketing	0	826	743	805	968	869	753	864	829	1,076	898	0
General & administrative	0	754	632	572	442	992	505	501	528	652	553	0
Other expenses	90	424	6,561	37	2,278	34	253	250	170	0	106	12,933
Operating income	2,623	1,612	−4,322	2,644	888	2,452	2,237	2,474	3,327	2,988	2,586	−10,394
	−305	41	−164	−591	68	−285	−588	−45	314	−910	−6	140
Interest income	106	0	108	35	52	85	94	73	88	95	0	0
Interest expense	232	252	254	237	238	249	260	254	256	255	240	247
Other non-operating income	73	−293	−90	354	−306	36	328	−209	−570	655	235	−387
Income before tax	2,318	1,653	−4,486	2,053	956	2,167	1,649	2,429	3,641	2,078	2,580	−10,254
Income tax expense	146	237	−315	438	−297	385	334	468	589	−105	559	242
Net income from continuing operations	2,172	1,416	−4,171	1,615	1,253	1,782	1,315	1,961	3,052	2,183	2,021	−10,496
Other adjustments	0	1	1	−1	0	1	0	−1	0	0	0	0
Net income	2,180	1,429	−4,170	1,614	1,253	1,783	1,315	1,960	3,052	2,183	2,021	−10,496
EPS, basic	$1.75	$1.15	−$3.34	$1.29	$1.00	$1.43	$1.06	$1.57	$2.46	$1.76	$1.63	−$8.45
EPS, diluted	$1.73	$1.14	−$3.34	$1.29	$1.00	$1.42	$1.04	$1.56	$2.43	$1.74	$1.61	−$8.45
Weighted average shares, basic	1,248	1,248	1,247	1,247	1,247	1,248	1,246	1,245	1,243	1,242	1,242	1,243
Weighted average shares, diluted	1,257	1,256	1,247	1,251	1,254	1,259	1,259	1,255	1,254	1,253	1,254	1,243
EBITDA	3,234	2,593	−3,542	2,984	1,884	3,109	2,605	3,374	4,583	3,020	3,040	−10,007
Depreciation & amortization	684	688	690	694	690	693	696	691	686	687	689	0
EBIT	2,550	1,905	−4,232	2,290	1,194	2,416	1,909	2,683	3,897	2,333	2,351	−10,007